Generation of An Endogenous FGFR2–BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells
Fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene fusions are <i>bona fide</i> oncogenic drivers in 10–15% of intrahepatic cholangiocarcinoma (CCA), yet currently there are no cell lines publically available to study endogenous <i>FGFR2</i> gene fusions. The...
Main Authors: | Andreas Reicher, Antoneicka L Harris, Felix Prinz, Tobias Kiesslich, Miaoyan Wei, Rupert Öllinger, Roland Rad, Martin Pichler, Lawrence N Kwong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/7/2460 |
Similar Items
-
FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
by: Ying X, et al.
Published: (2019-11-01) -
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01) -
Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01) -
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
by: Anuhya Kommalapati, et al.
Published: (2021-06-01) -
Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
by: Alexander Scheiter, et al.
Published: (2021-03-01)